Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGONNASDAQ:KNSANASDAQ:RGNXNASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$25.44-1.2%$23.26$14.80▼$40.47$1.94B1.08826,924 shs653,529 shsKNSAKiniksa Pharmaceuticals$26.89+3.6%$23.26$17.38▼$28.56$1.96B0.07487,154 shs590,247 shsRGNXREGENXBIO$9.71-1.5%$7.82$5.04▼$15.39$487.05M1.11880,673 shs645,180 shsTARSTarsus Pharmaceuticals$42.98+0.0%$47.73$20.08▼$57.28$1.81B0.94699,767 shs324,236 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology-1.24%+0.04%+22.74%-8.65%-17.43%KNSAKiniksa Pharmaceuticals+3.62%+2.44%+28.78%+34.32%+39.54%RGNXREGENXBIO-1.52%+9.22%+9.13%+33.56%-37.23%TARSTarsus Pharmaceuticals+0.02%-1.65%-14.04%-10.16%+20.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGONCG Oncology2.2214 of 5 stars4.51.00.00.02.60.80.0KNSAKiniksa Pharmaceuticals2.9162 of 5 stars3.52.00.00.03.43.30.6RGNXREGENXBIO4.1942 of 5 stars3.42.00.04.62.53.30.6TARSTarsus Pharmaceuticals3.239 of 5 stars4.51.00.00.03.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGONCG Oncology 3.00Buy$58.22128.86% UpsideKNSAKiniksa Pharmaceuticals 3.00Buy$38.8044.29% UpsideRGNXREGENXBIO 2.83Moderate Buy$31.63225.70% UpsideTARSTarsus Pharmaceuticals 3.00Buy$66.3354.34% UpsideCurrent Analyst Ratings BreakdownLatest RGNX, KNSA, CGON, and TARS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $52.005/5/2025TARSTarsus PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$46.00 ➝ $51.005/2/2025CGONCG OncologyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$41.005/2/2025TARSTarsus PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $84.004/29/2025CGONCG OncologyRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$66.00 ➝ $68.004/29/2025KNSAKiniksa PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/28/2025CGONCG OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$75.00 ➝ $75.004/28/2025CGONCG OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.004/17/2025RGNXREGENXBIOThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.004/16/2025CGONCG OncologyScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$23.004/16/2025KNSAKiniksa PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGONCG Oncology$662K2,929.25N/AN/A($1.94) per share-13.11KNSAKiniksa Pharmaceuticals$481.17M4.08N/AN/A$6.23 per share4.32RGNXREGENXBIO$156.72M3.11N/AN/A$7.09 per share1.37TARSTarsus Pharmaceuticals$233.67M7.73N/AN/A$5.95 per share7.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGONCG Oncology-$48.61M-$1.51N/AN/AN/A-10,642.98%-18.97%-15.36%N/AKNSAKiniksa Pharmaceuticals$14.08M-$0.25N/A107.56N/A-2.36%-7.31%-5.95%7/22/2025 (Estimated)RGNXREGENXBIO-$263.49M-$3.11N/AN/AN/A-283.19%-70.65%-41.68%8/7/2025 (Estimated)TARSTarsus Pharmaceuticals-$135.89M-$2.73N/AN/AN/A-103.64%-55.86%-39.28%8/6/2025 (Estimated)Latest RGNX, KNSA, CGON, and TARS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CGONCG Oncology-$0.36-$0.45-$0.09-$0.45$0.53 million$0.05 million5/12/2025Q1 2025RGNXREGENXBIO$0.41$0.12-$0.29$0.12$105.35 million$89.01 million5/1/2025Q1 2025TARSTarsus Pharmaceuticals-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 million4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals$0.02$0.11+$0.09$0.11$128.35 million$137.79 million3/25/2025Q4 2024CGONCG Oncology-$0.37-$0.48-$0.11-$0.48$0.11 million$0.46 million3/13/2025Q4 2024RGNXREGENXBIO-$1.27-$1.01+$0.26-$1.01$23.70 million$21.21 million2/25/2025Q4 2024KNSAKiniksa Pharmaceuticals-$0.06-$0.12-$0.06-$0.12$123.42 million$122.50 million2/25/2025Q4 2024TARSTarsus Pharmaceuticals-$0.68-$0.60+$0.08-$0.60$58.80 million$66.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGONCG OncologyN/AN/AN/AN/AN/AKNSAKiniksa PharmaceuticalsN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGONCG OncologyN/A35.3235.32KNSAKiniksa PharmaceuticalsN/A3.242.95RGNXREGENXBION/A3.053.05TARSTarsus Pharmaceuticals0.305.425.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGONCG Oncology26.56%KNSAKiniksa Pharmaceuticals53.95%RGNXREGENXBIO88.08%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipCGONCG Oncology7.40%KNSAKiniksa Pharmaceuticals54.57%RGNXREGENXBIO12.79%TARSTarsus Pharmaceuticals8.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGONCG Oncology6176.23 millionN/AOptionableKNSAKiniksa Pharmaceuticals22072.97 million32.80 millionOptionableRGNXREGENXBIO37050.16 million43.04 millionOptionableTARSTarsus Pharmaceuticals5042.01 million35.07 millionOptionableRGNX, KNSA, CGON, and TARS HeadlinesRecent News About These CompaniesTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Bank of America Corp DEMay 23 at 3:17 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Buy" from BrokeragesMay 23 at 1:33 AM | americanbankingnews.com59,204 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.May 22 at 7:39 AM | marketbeat.comOMERS ADMINISTRATION Corp Buys Shares of 7,400 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 22 at 4:23 AM | marketbeat.comTarsus Pharmaceuticals at H.C. Wainwright: Expanding Horizons with XdemvyMay 21 at 5:51 PM | investing.comTFG Asset Management GP Ltd Sells 414,117 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 20, 2025 | marketbeat.comToronto Dominion Bank Acquires New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 20, 2025 | marketbeat.comMillennium Management LLC Increases Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 20, 2025 | marketbeat.comDeutsche Bank AG Raises Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 19, 2025 | marketbeat.comRTW Investments LP Has $179.21 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 18, 2025 | marketbeat.comNumerai GP LLC Purchases Shares of 18,668 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 17, 2025 | marketbeat.comParadigm Biocapital Advisors LP Has $140.19 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 16, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Northern Trust CorpMay 16, 2025 | marketbeat.comTarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 14, 2025 | zacks.comIntegral Health Asset Management LLC Has $19.38 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 14, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Grows Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 14, 2025 | marketbeat.comEnsign Peak Advisors Inc Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 13, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Schonfeld Strategic Advisors LLCMay 13, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by The Manufacturers Life Insurance CompanyMay 13, 2025 | marketbeat.comTarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay OffMay 12, 2025 | seekingalpha.comTudor Investment Corp ET AL Takes $769,000 Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGNX, KNSA, CGON, and TARS Company DescriptionsCG Oncology NASDAQ:CGON$25.44 -0.32 (-1.24%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$25.62 +0.17 (+0.69%) As of 05/23/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Kiniksa Pharmaceuticals NASDAQ:KNSA$26.89 +0.94 (+3.62%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$26.90 +0.00 (+0.02%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.REGENXBIO NASDAQ:RGNX$9.71 -0.15 (-1.52%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.91 +0.20 (+2.05%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Tarsus Pharmaceuticals NASDAQ:TARS$42.98 +0.01 (+0.02%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$43.00 +0.02 (+0.03%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
